🇺🇸 FDA
Pipeline program

Adagrasib

ETOP 22-22 ADEPPT

Phase 2 small_molecule active

Quick answer

Adagrasib for Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2) Cohort 1 or elderly (≥70 years) (ECOG PS=0-1) Cohort 2 is a Phase 2 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Partner Therapeutics Limited
Indication
Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2) Cohort 1 or elderly (≥70 years) (ECOG PS=0-1) Cohort 2
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials